Teratogenicity of Antiepileptic Medications

ABSTRACT

Antiepileptic drugs (AEDs) are frequently used to treat several conditions that are common in women of childbearing age, including epilepsy, headaches, and mood disorders. Moreover, as in the case of epilepsy and severe psychiatric disease, clinicians frequently do not have the option of stopping these medications or switching to another class of drugs. Overall, AEDs have been associated with an increased risk of major congenital malformations, minor anomalies, specific congenital syndromes, and developmental disorders seen in childhood. However, the differential effects of individual AEDs remain uncertain. Data are accumulating which strongly suggest that these risks are highest in patients receiving polypharmacy and valproate. There is also modest evidence to suggest an increased risk for phenobarbital. While other older AEDs appear to carry some teratogenic risk, there is not adequate evidence to further stratify their risk. Clinical and basic science research regarding newer AEDs suggests equivalent, if not safer, profiles compared with older AEDs, but these data are inconclusive. Management of women with epilepsy should include a discussion of these risks, prophylactic treatment with folic acid, and the minimal use of polypharmacy and valproate needed to maintain optimum seizure control.

KEYWORDS

Antiepileptic medications - teratogens - epilepsy - congenital malformations

REFERENCES

• 1 Mueller-Kueppers M. Embryopathy during pregnancy caused by taking anticonvulsants.  Acta Paedopsychiatr. 1963;  30 401-405
• 2 Perucca E. Birth defects after prenatal exposure to antiepileptic drugs.  Lancet Neurol. 2005;  4 781-786
• 3 Motamedi G K, Meador K J. Antiepileptic drugs and neurodevelopment.  Curr Neurol Neurosci Rep. 2006;  6 341-346
• 4 Palmieri C, Canger R. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing?.  CNS Drugs. 2002;  16 755-764
• 5 Rogawski M A, Loscher W. The neurobiology of antiepileptic drugs.  Nat Rev Neurosci. 2004;  5 553-564
• 6 Hanson J W, Smith D W. The fetal hydantoin syndrome.  J Pediatr. 1975;  87 285-290
• 7 Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy.  Reprod Toxicol. 2006;  22 214-226
• 8 Freeman M P, Gelenberg A J. Bipolar disorder in women: reproductive events and treatment considerations.  Acta Psychiatr Scand. 2005;  112 88-96
• 9 Pennell P B. Pregnancy in women who have epilepsy.  Neurol Clin. 2004;  22 799-820
• 10 Barrett C, Richens A. Epilepsy and pregnancy: report of an Epilepsy Research Foundation Workshop.  Epilepsy Res. 2003;  52 147-187
• 11 Hallak M, Kupsky W J, Hotra J W et al.. Fetal rat brain damage caused by maternal seizure activity: prevention by magnesium sulfate.  Am J Obstet Gynecol. 1999;  181 828-834
• 12 Nei M, Daly S, Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate.  Neurology. 1998;  51 904-906
• 13 Adab N, Kini U, Vinten J et al.. The longer term outcome of children born to mothers with epilepsy.  J Neurol Neurosurg Psychiatry. 2004;  75 1575-1583
• 14 Partington M D, McLone D G. Hereditary factors in the etiology of neural tube defects: results of a survey.  Pediatr Neurosurg. 1995;  23 311-316
• 15 Duncan S, Mercho S, Lopes-Cendes I et al.. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality.  Epilepsia. 2001;  42 750-753
• 16 Kallen B. Epidemiology of Human Reproduction. Boca Raton; CRC Press 1988: 133-137
• 17 Fried S, Kozer E, Nulman I et al.. Malformation rates in children of women with untreated epilepsy: a meta-analysis.  Drug Saf. 2004;  27 197-202
• 18 Holmes L B, Harvey E A, Coull B A et al.. The teratogenicity of anticonvulsant drugs.  N Engl J Med. 2001;  344 1132-1138
• 19 Lindhout D, Omtzigt J G. Pregnancy and the risk of teratogenicity.  Epilepsia. 1992;  33(suppl 4) S41-S48
• 20 Strickler S M, Dansky L V, Miller M A et al.. Genetic predisposition to phenytoin-induced birth defects.  Lancet. 1985;  2 746-749
• 21 Van der Put N M, Eskes T K, Blom H J. Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis.  QJM. 1997;  90 111-115
• 22 Dean J C, Moore S J, Osborne A et al.. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene.  Clin Genet. 1999;  56 216-220
• 23 Finnell R H, Waes J G, Eudy J D et al.. Molecular basis of environmentally induced birth defects.  Annu Rev Pharmacol Toxicol. 2002;  42 181-208
• 24 [No authors listed] . Practice parameter: Management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 1998;  51 944-948
• 25 [No authors listed] . Guidelines for the care of women of childbearing age with epilepsy. Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy.  Epilepsia. 1993;  34 588-589
• 26 Meador K J, Baker G A, Finnell R H et al.. In utero antiepileptic drug exposure: fetal death and malformations.  Neurology. 2006;  67 407-412
• 27 Pennell P B. The importance of monotherapy in pregnancy.  Neurology. 2003;  60(suppl 4) S31-S38
• 28 Holmes L B, Wyszynski D F, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience.  Arch Neurol. 2004;  61 673-678
• 29 Polifka J E, Friedman J M. Medical genetics: 1. Clinical teratology in the age of genomics.  CMAJ. 2002;  167 265-273
• 30 Finnell R H, Nau H, Yerby M S. General principles: teratogenicity of antiepileptic drugs. In: Levy RH, Matson BS Antiepileptic Drugs. 4th ed. New York, NY; Raven Press 1995: 209-230
• 31 Lindhout D, Omtzigt J G. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age.  Epilepsia. 1994;  35(suppl 4) S19-S28
• 32 Ardinger H H, Atkin J F, Blackston R D et al.. Verification of the fetal valproate syndrome phenotype.  Am J Med Genet. 1988;  29 171-185
• 33 Jones K L, Lacro R V, Johnson K A et al.. Pattern of malformations in the children of women treated with carbamazepine during pregnancy.  N Engl J Med. 1989;  320 1661-1666
• 34 Jones K L, Johnson K A, Chambers C C. Pregnancy outcome in women treated with phenobarbital monotherapy.  Teratology. 1992;  45 453-454
• 35 Wilkie A O, Morris-Kay G M. Genetics of craniofacial development and malformation.  Nat Rev Genet. 2001;  2 458-468
• 36 Reinisch J M, Sanders S A, Mortensen E L et al.. In utero exposure to phenobarbital and intelligence deficits in adult men.  JAMA. 1995;  274 1518-1525
• 37 Dean J C, Hailey H, Moore S J et al.. Long-term health and neurodevelopment in children exposed to antiepileptic drugs before birth.  J Med Genet. 2002;  39 251-259
• 38 Meador K J, Browning N, Cohen M J et al.. Cognitive outcomes at 2 years old in children of women with epilepsy differ as function of in utero antiepileptic drug.  Neurology. 2007;  68(suppl 1) A337
• 39 Schaefer G B, Sheth R D, Bodensteiner J B. Cerebral dysgenesis: an overview.  Neurol Clin. 1994;  12 773-788
• 40 Marsh E D, Brooks-Kayal A R, Porter B E. Seizures and antiepileptic drugs: does exposure alter normal brain development?.  Epilepsia. 2006;  47 1999-2010
• 41 Kaindl A M, Asimiadou S, Manthey D et al.. Antiepileptic drugs and the developing brain.  Cell Mol Life Sci. 2006;  63 399-413
• 42 Cadigan K M, Nusse R. WNT signaling: a common theme in animal development.  Genes Dev. 1997;  11 3286-3305
• 43 Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-developmental effects of valproic acid.  Crit Rev Toxicol. 2005;  35(8–9) 727-738
• 44 Dansky L V, Rosenblatt D S, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy.  Neurology. 1992;  42(suppl 5) S32-S42
• 45 Bittigau P, Sifringer M, Genz K et al.. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain.  Proc Natl Acad Sci U S A. 2002;  99 15089-15094
• 46 Bjerkedal T, Czeizel A, Goujard J et al.. Valproic acid and spina bifida.  Lancet. 1982;  2 1096
• 47 Samren E B, van Duijn C M, Koch S et al.. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy.  Epilepsia. 1997;  38 981-990
• 48 Wyszynski D F, Nambisan M, Surve T et al.. Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy.  Neurology. 2005;  64 961-965
• 49 Vajda F J, Eadie M J. Maternal valproate dosage and foetal malformations.  Acta Neurol Scand. 2005;  112 137-143
• 50 Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide population-based register study.  Acta Paediatr. 2004;  93 174-176
• 51 Artama M, Auvinen A, Raudaskoski T et al.. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.  Neurology. 2005;  64 1874-1878
• 52 Morrow J, Russell A, Guthrie E et al.. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2006;  77 193-198
• 53 Cunnington M, Tennis P. International Lamotrigine Pregnancy Registry Scientific Advisory Committee . Lamotrigine and the risk of malformations in pregnancy.  Neurology. 2005;  64 955-960
• 54 Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study.  BMJ. 1973;  2 442-448
• 55 Dolovich L R, Addis A, Vaillancourt J M et al.. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.  BMJ. 1998;  317 839-843
• 56 Lin A E, Peller A J, Westgate M N et al.. Clonazepam use in pregnancy and the risk of malformations.  Birth Defects Res A Clin Mol Teratol. 2004;  70 534-536
• 57 Scolnik D, Nulman I, Rovet J et al.. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy.  JAMA. 1994;  271 767-770
• 58 Loring D W, Meador K J, Thompson W O. Neurodevelopment after in utero exposure to phenytoin and carbamazepine.  JAMA. 1994;  272 850-851
• 59 Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy.  Curr Med Res Opin. 2005;  21 693-701
• 60 Cunnington M, Ferber S, Quartey G. International Lamotrigine Pregnancy Registry Scientific Advisory Committee . Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.  Epilepsia. 2007;  48 1207-1210
• 61 Hunt S, Craig J, Russell A et al.. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.  Neurology. 2006;  67 1876-1879
• 62 Ohtahara S, Yamatogi Y. Erratum to “Safety of zonisamide therapy: prospective follow-up survey”.  Seizure. 2007;  16 87-93
• 63 Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.  Epilepsy Behav. 2003;  4 310-317
• 64 Marchi N S, Azoubel R, Tognola W A. Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study.  Arq Neuropsiquiatr. 2001;  59 362-364
• 65 Vila Cerén C, Demestre Guasch X, Raspall Torrent F et al.. Topiramate and pregnancy: neonate with bone anomalies.  An Pediatr (Barc). 2005;  63 363-365
• 66 Finer L B, Henshaw S K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.  Perspect Sex Reprod Health. 2006;  38 90-96
• 67 Schwarz E B, Postlethwaite D A, Yun-yi H et al.. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.  Ann Intern Med. 2007;  147 370-376
• 68 Pitkin R M. Folate and neural tube defects.  Am J Clin Nutr. 2007;  85 285S-288S
• 69 Centers for Disease Control . Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects.  MMWR Recomm Rep. 1992;  41 1-7
• 70 Yerby M S. Management issues for women with epilepsy: neural tube defects and folic acid supplementation.  Neurology. 2003;  61(suppl 2) S23-S26
• 71 Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy.  Neurology. 2003;  60 575-579
• 72 Vajda F J, Eadie M J. Maternal valproate dosage and foetal malformations.  Acta Neurol Scand. 2005;  112 137-143
• 73 Pennell P B. Pregnancy in the woman with epilepsy: maternal and fetal outcomes.  Semin Neurol. 2002;  22 299-308
• 74 Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating mood disorders during pregnancy: safety considerations.  Drug Saf. 2005;  28 695-706
• 75 Pennell P B. Antiepileptic drug pharmacokinetics during pregnancy and lactation.  Neurology. 2003;  61(suppl 2) S35-S42
• 76 Moslet U, Hansen E S. A review of vitamin K, epilepsy and pregnancy.  Acta Neurol Scand. 1992;  85 39-43
• 77 Autret-Leca E, Jonville-Béra A P. Vitamin K in neonates: how to administer, when and to whom.  Paediatr Drugs. 2001;  3 1-8